Posaconazole IV

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

2 competitors in Invasive Fungal Infection

#DrugCompanyPhaseTrials

1

Noxafil

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 3

42

Posaconazole IV

Merck & Co.

Phase 2

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunocompromised2 trials

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Terminated·Merck & Co.·Phase 1·NCT01716234·142 enrolled

Safety and Pharmacokinetics of Intravenous and Oral Posaconazole in Immunocompromised Children (MK-5592-097)

Completed·Merck & Co.·Phase 1·NCT02452034·118 enrolled

Invasive Fungal Infections1 trial

Evaluation of Treatment and Prophylaxis of Invasive Fungal Infections in Immuncompromised Patients in Austria (Study P05532)(WITHDRAWN)

Withdrawn·Merck & Co.··NCT00704951

Aspergillosis1 trial

Posaconazole (MK-5592) Intravenous and Oral in Children With Invasive Aspergillosis (IA) (MK-5592-104)

Completed·Merck & Co.·Phase 2·NCT04218851·31 enrolled

Invasive Fungal Infection1 trial

A Phase 2, Open-Label, Single-Arm, Sequential-Panel Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Posaconazole (POS, MK-5592) Intravenous and Powder for Oral Suspension Formulations in Pediatric Participants From Birth to Less Than 2 Years of Age With Possible, Probable, or Proven Invasive Fungal Infection

Recruiting·Merck & Co.·Phase 2·NCT04665037·40 enrolled

Details

Drug Info

Related News